doi: 10.3747/co.v17i1.473.
Management of hot flashes in women with breast cancer
Affiliations
- PMID: 20179808
- PMCID: PMC2826783
- DOI: 10.3747/co.v17i1.473
Item in Clipboard
Management of hot flashes in women with breast cancer
Curr Oncol.
2010 Feb.
Abstract
Hormone-suppression therapies are used for the treatment of breast cancer in the adjuvant and metastatic settings alike. However, side effects-including hot flashes-are frequently reported by patients as a cause of therapy discontinuation. This paper presents an overview of hormonal therapies and the evidence-based management options for hot flashes, summarized in a treatment algorithm.
Keywords: Breast cancer; aromatase inhibitors; hot flashes; tamoxifen.
Figures
Treatment algorithm for hot flashes, based on the experience of the London Regional Cancer Program.
Similar articles
-
[Hot flushes and breast cancer with positive hormone receptors: Mechanisms and management].Bull Cancer. 2020 Nov;107(11):1171-1185. doi: 10.1016/j.bulcan.2020.07.005. Epub 2020 Sep 25. Bull Cancer. 2020. PMID: 32988609 Review. French.
-
Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study.Ann Intern Med. 2000 May 16;132(10):788-93. doi: 10.7326/0003-4819-132-10-200005160-00004. Ann Intern Med. 2000. PMID: 10819701 Clinical Trial.
-
[Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects].Klin Onkol. 2016 Fall;29 Suppl 3:S39-49. doi: 10.14735/amko20163S39. Klin Onkol. 2016. PMID: 28118723 Czech.
-
Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective.Am J Surg. 2006 Oct;192(4):496-8. doi: 10.1016/j.amjsurg.2006.06.018. Am J Surg. 2006. PMID: 16978958
-
Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy.Breast Cancer Res Treat. 2008 Jan;107(2):167-80. doi: 10.1007/s10549-007-9548-1. Epub 2007 Sep 18. Breast Cancer Res Treat. 2008. PMID: 17876703 Review.
Cited by
-
Comparison of physical interventions, behavioral interventions, natural health products, and pharmacologics to manage hot flashes in patients with breast or prostate cancer: protocol for a systematic review incorporating network meta-analyses.Syst Rev. 2015 Aug 27;4:114. doi: 10.1186/s13643-015-0099-y. Syst Rev. 2015. PMID: 26307105 Free PMC article.
-
Bee pollen and honey for the alleviation of hot flushes and other menopausal symptoms in breast cancer patients.Mol Clin Oncol. 2015 Jul;3(4):869-874. doi: 10.3892/mco.2015.559. Epub 2015 May 4. Mol Clin Oncol. 2015. PMID: 26171198 Free PMC article.
-
The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation.Support Care Cancer. 2023 Nov 27;31(12):719. doi: 10.1007/s00520-023-08170-y. Support Care Cancer. 2023. PMID: 38008817
-
Adverse effects of non-hormonal pharmacological interventions in breast cancer survivors, suffering from hot flashes: A systematic review and meta-analysis.Breast Cancer Res Treat. 2016 Nov;160(2):223-236. doi: 10.1007/s10549-016-4002-x. Epub 2016 Oct 5. Breast Cancer Res Treat. 2016. PMID: 27709351 Free PMC article.
-
Physiologically Active Molecules and Functional Properties of Soybeans in Human Health-A Current Perspective.Int J Mol Sci. 2021 Apr 14;22(8):4054. doi: 10.3390/ijms22084054. Int J Mol Sci. 2021. PMID: 33920015 Free PMC article. Review.
References
-
- Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 2001;92:2247–58. - PubMed
-
- Coates AS, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study big 1-98. J Clin Oncol. 2007;25:486–92. - PubMed
-
- Coombes RC, Hall E, Gibson LJ, et al. on behalf of the Inter-group Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–92. - PubMed
-
- Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21:602–6. - PubMed
-
- Oldenhave A, Jaszmann LJ, Haspels AA, Everaerd WT. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol. 1993;168:772–80. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
